News

Neupharma informs to have acquired 15% of Plumestars

Neupharma informs to have acquired 15% of Plumestars

21 January 2019
Neupharma informs to have acquired 15% of Plumestars - www.plumestars.com – a research company based in Parma focused on the development of orphan drugs for rare diseases with a specific know-how in inhalatory formulations.
The European Commission granted the designation of Orphan Drug to Teicoplanin

The European Commission granted the designation of Orphan Drug to Teicoplanin

23 August 2017
The European Commission granted the designation of Orphan Drug to Teicoplanin in inhalation formulation for Cystic Fibrosis, formulation developed by Neupharma in partnership with the non-profit Rare Partners